Aripiprazole: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''aripiprazole''' (pronunciation: ay ri pip' ray zole) is an atypical or second generation anti-psychotic agent that "has both presynaptic dopamine autoreceptor a...) |
imported>Robert Badgett mNo edit summary |
||
| Line 1: | Line 1: | ||
In [[medicine]], '''aripiprazole''' (pronunciation: ay ri pip' ray zole) is an atypical or second generation [[anti-psychotic agent]] that "has both presynaptic [[dopamine]] autoreceptor agonistic activity and postsynaptic D<sub>2</sub> receptor antagonistic activity; structure given in first source; use associated with hyperglycemia."<ref>{{MeSH}}</ref> | In [[medicine]], '''aripiprazole''' (pronunciation: ay ri pip' ray zole) is an atypical or second generation [[anti-psychotic agent]] that "has both presynaptic [[dopamine]] autoreceptor agonistic activity and postsynaptic D<sub>2</sub> receptor antagonistic activity; structure given in first source; use associated with hyperglycemia."<ref>{{MeSH}}</ref> | ||
In the [[United States]], the [[Food and Drug Administration]] has approved the use of aripiprazole for the treatment of [[schizophrenia]], [[bipolar disorder|bipolar I disorder]], [[major depressive disorder]], irritability associated with [[autistic disorder]] agitation associated with [[schizophrenia]] or mania from [[bipolar disorder]]. The trade name is | In the [[United States]], the [[Food and Drug Administration]] has approved the use of aripiprazole for the treatment of [[schizophrenia]], [[bipolar disorder|bipolar I disorder]], [[major depressive disorder]], irritability associated with [[autistic disorder]] agitation associated with [[schizophrenia]] or mania from [[bipolar disorder]]. The trade name is Abilify™. Although not approved for the treatment of [[dementia]], aripiprazole has been studied in this setting. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 16:47, 3 June 2010
In medicine, aripiprazole (pronunciation: ay ri pip' ray zole) is an atypical or second generation anti-psychotic agent that "has both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity; structure given in first source; use associated with hyperglycemia."[1]
In the United States, the Food and Drug Administration has approved the use of aripiprazole for the treatment of schizophrenia, bipolar I disorder, major depressive disorder, irritability associated with autistic disorder agitation associated with schizophrenia or mania from bipolar disorder. The trade name is Abilify™. Although not approved for the treatment of dementia, aripiprazole has been studied in this setting.
References
- ↑ Anonymous (2024), Aripiprazole (English). Medical Subject Headings. U.S. National Library of Medicine.